Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.12.2012 | short review | Ausgabe 4/2012

memo - Magazine of European Medical Oncology 4/2012

Significant heterogeneity between centers during early evaluation of the first Turkish multi-centric study in the treatment of childhood acute lymphoblastic leukemia

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 4/2012
Autor:
Lebriz Yüksel-Soycan

Abstract

Background

The key of success in the treatment of pediatric acute lymphoblastic leukemia (ALL) has been the conduct of multi-centric clinical studies. With the aim of repeating the favorable results reported by the BFM group and reaching uniformity in diagnosis and treatment, the first Turkish multi-centric study in the treatment of pediatric ALL, BFM-TR ALL 2000, was opened to patient accrual in January 2000.

Methods

A total of 2,685 patients 0–18 years old from 32 different centers were registered until 31 December 2010. The treatment was a modified BFM-ALL 95 protocol. There was a common database, but no central morphological review.

Results

The median age was 5.2 years and the male:female ratio was 1.4. The median white blood cell (WBC) count was 13,900/μl and 14 % of the patients had a WBC count > 100,000/μl. Initial central nervous system involvement was seen in 3.5 % (range 0–13 %) of the patients and 18 % (4–13 %) had T-ALL. During induction, 0.5 % of the patients abandoned treatment and 2.5 % toxic deaths (range 0–9.2 %) resulted in 96.4 % remission rate. Non-relapse related mortality (8.7 %, range 0–15.9 %) was an important cause of failure early in remission and 3 % of the patients dropped-out before treatment was completed. Poor prednisone response rate was 14.5 % (range 4.3–27.2 %) and non-remission rate on day 33 was 4.5 % (range 0–23 %).

Conclusions

Lack of a centralized laboratory diagnosis or reference evaluation precludes any explanation of the heterogeneity of the clinical and laboratory values. The high percentage of deaths in remission is a major cause of failure.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2012

memo - Magazine of European Medical Oncology 4/2012 Zur Ausgabe